Neurocrine Biosciences (NBIX) Gross Margin (2017 - 2025)
Historic Gross Margin for Neurocrine Biosciences (NBIX) over the last 8 years, with Q4 2025 value amounting to 97.82%.
- Neurocrine Biosciences' Gross Margin fell 7000.0% to 97.82% in Q4 2025 from the same period last year, while for Dec 2025 it was 98.18%, marking a year-over-year decrease of 3800.0%. This contributed to the annual value of 98.18% for FY2025, which is 3800.0% down from last year.
- Latest data reveals that Neurocrine Biosciences reported Gross Margin of 97.82% as of Q4 2025, which was down 7000.0% from 98.24% recorded in Q3 2025.
- Neurocrine Biosciences' Gross Margin's 5-year high stood at 98.93% during Q2 2021, with a 5-year trough of 97.46% in Q2 2023.
- In the last 4 years, Neurocrine Biosciences' Gross Margin had a median value of 98.39% in 2025 and averaged 98.32%.
- Its Gross Margin has fluctuated over the past 5 years, first surged by 9800bps in 2024, then crashed by -7000bps in 2025.
- Quarter analysis of 4 years shows Neurocrine Biosciences' Gross Margin stood at 98.58% in 2021, then dropped by 0bps to 98.35% in 2023, then increased by 0bps to 98.52% in 2024, then fell by -1bps to 97.82% in 2025.
- Its Gross Margin stands at 97.82% for Q4 2025, versus 98.24% for Q3 2025 and 98.36% for Q2 2025.